Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
RESEARCH TOOLSreports
BRNS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.68 - $3.64
Previous CloseN/A
Volume10.26K
Average Volume (3M)20.13K
Market Cap
$27.44M
Enterprise Value-$52.10M
Total Cash (Recent Filing)$110.66M
Total Debt (Recent Filing)$12.01M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
May 08, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding40,228,455
10 Day Avg. Volume25,545
30 Day Avg. Volume20,131
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.66
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.48
Enterprise Value/Ebitda0.94
Forecast
1Y Price Target
$4.50Price Target Upside561.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Barinthus Biotherapeutics News
PremiumCompany Announcements
Barinthus Bio Reports 2024 Financial Results and Strategic Focus
PremiumCompany Announcements
Barinthus Biotherapeutics Restructures to Focus on Immunotherapy---
Bulls Say, Bears Say
Bulls Say
Cash ManagementThe company has extended its cash runway to the start of 2027, based on expected cost savings from the corporate restructuring.
Clinical Trial ProgressThe company is slated to present updated interim data from the Phase 2b trial (HBV003) of VTP-300 in chronic hepatitis B, which could further solidify VTP-300’s position as a potential key component of a functional cure for CHB.
Financial PerformanceRevenue was $15.0M, which was the company’s share of royalties as a result of prior commercial sales of Vaxzevria by AstraZeneca, beating our projection of zero revenue.
Bears Say
Clinical Trial RiskThe probability of approval for VTP-300 has been reduced from 45% to 15%.
Earnings ReportFor 4Q24, net loss was $20.5M, or ($0.51) per share, more than the estimated loss of $11.5M due to $12.2M of goodwill impairment.
Regulatory RiskRisks include failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.
---
Ownership Overview
3.65%
Insiders
0.03%
Mutual Funds
24.45% Other Institutional Investors
71.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.68 and its highest was $3.64 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $27.44M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is May 08, 2025 which is in 31 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Mar 20, 2025. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.371 by -$0.139.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.36.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,228,455 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.371. Following the earnings report the stock price went up 2.02%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
---
Barinthus Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (561.76% Upside)
$4.50 (561.76% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.41%
12-Months-Change
Fundamentals
Return on Equity
-38.49%
Trailing 12-Months
Asset Growth
-24.61%
Trailing 12-Months
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics (BRNS) is a cutting-edge biotechnology company focused on developing innovative therapies and solutions in the biotherapeutics sector. The company specializes in creating advanced treatments for complex diseases, leveraging state-of-the-art technology and research to deliver groundbreaking products aimed at improving patient outcomes.
---
BRNS Stock 12 Month Forecast
Average Price Target
$4.50
▲(561.76% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering BRNS
1 Year
1 Year Success Rate
2/18 ratings generated profit
1 Year Average Return
-36.71%
reiterated a buy rating 18 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -36.71% per trade.
---